GlassScriptPhysician profile
Tracey Jones
NPI 1043361355
$12,983.81
in general payments reported to CMS, 2019-2025
27 companies · $2,465 in 2025
The $2,465 reported for 2025 was more than what 91% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,049 · 2020: $1,277 · 2021: $1,883 · 2022: $1,336 · 2023: $1,892 · 2024: $2,082 · 2025: $2,465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,439.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,439.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,991.86 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,796.61 | 2019-2025 | Rexulti, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $1,246.55 | 2019-2025 | Invega Sustenna, Invega Trinza |
| Takeda Pharmaceuticals U.S.A., INC. | $1,076.62 | 2019-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,065.36 | 2022-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $881.43 | 2019-2022 | |
| Lundbeck LLC | $738.43 | 2019-2025 | Rexulti |
| Bausch Health US, LLC | $727.37 | 2019-2025 | Aplenzin |
| Allergan, INC. | $553.78 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $497.72 | 2025 | Cobenfy |
| Corium, LLC | $331.54 | 2022-2025 | Azstarys |
| Adlon Therapeutics L.P. | $330.66 | 2019-2021 | |
| Axsome Therapeutics, INC. | $313.48 | 2023-2025 | Auvelity |
| Ironshore Pharmaceuticals INC. | $299.56 | 2019-2024 | Jornay Pm |
| Alkermes, INC. | $248.59 | 2021-2025 | Lybalvi |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $157.52 | 2022-2023 | Quviviq |
| Vanda Pharmaceuticals INC. | $139.01 | 2025 | Fanapt |
| Arbor Pharmaceuticals, INC. | $138.84 | 2019-2020 | |
| Harmony Biosciences LLC | $134.78 | 2024-2025 | |
| Supernus Pharmaceuticals, INC. | $86.73 | 2024-2025 | Qelbree |
| Avanir Pharmaceuticals, INC. | $61.37 | 2019 | |
| Neuronetics, INC. | $44.03 | 2019 | |
| Jazz Pharmaceuticals INC. | $40.87 | 2022 | |
| Eisai INC. | $24.25 | 2021 | |
| Neurocrine Biosciences, INC. | $21.34 | 2019 | |
| Collegium Pharmaceutical, INC. | $20.58 | 2025 | Jornay Pm |
| Tris Pharma INC | $14.93 | 2025 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracey Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.